IDT Biologika and Exothera Join on Vaccine Scale-up
IDT Biologika, a German CDMO specialized in vaccines, gene and immune therapy and oncolytic viruses, is collaborating with Belgian CDMO Exothera on developing a large-scale manufacturing process for viral vector-based vaccines. The two firms are currently conducting a feasibility study focused on the Modified Vaccinia Ankara (MVA) virus as a first project to come out of IDT’s broad range of vector technologies.
Exothera, which is specialized in the industrialization of vaccine and gene therapy processes, has successfully transferred IDT Biologika’s upstream process from small- to large-scale capability in the NevoLine Upstream platform of its parent company Univercells Technologies.
The NevoLine platform incorporates the scale-X structured fixed-bed bioreactor system that offers a range of options to upscale viral production from R&D to commercialization.
The partners said the innovative biomanufacturing technology will help to deliver cost-effective viral production. The collaboration between the two CDMOS is designed to demonstrate the application and increased performance of the platform at full commercial capacity.
Author: Dede Williams, Freelance Journalist
